Driehaus Capital Management

Total investments

34

Average round size

102M

Portfolio companies

31

Rounds per year

0.81

Follow on index

0.09

Exits

18

Stages of investment
Private Equity
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

Driehaus Capital Management is the famous VC, which was founded in 1982. The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the Chicago.

This Driehaus Capital Management works on 9 percentage points less the average amount of lead investments comparing to the other organizations. Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2019. The top amount of exits for fund were in 2019.

We also calculated 2 valuable employees in our database.

Among the most popular portfolio startups of the fund, we may highlight Orchard Therapeutics, Pulmonx, Alloptic. We can highlight the next thriving fund investment areas, such as Marketplace, Pharmaceutical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

The usual cause for the fund is to invest in rounds with 9 partakers. Despite the Driehaus Capital Management, startups are often financed by The Column Group, Remeditex Ventures, Montreux Equity Partners. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, ArrowMark Partners, RTW Investments LLC. In the next rounds fund is usually obtained by GMG Capital Partners, Athenian Venture Partners, Robb Kunz.

Show more

Investments analytics

Analytics

Total investments
34
Lead investments
0
Exits
18
Rounds per year
0.81
Follow on index
0.09
Investments by industry
  • Biotechnology (27)
  • Health Care (18)
  • Pharmaceutical (11)
  • Therapeutics (11)
  • Medical (9)
  • Show 17 more
Investments by region
  • United States (30)
  • United Kingdom (1)
  • Switzerland (1)
  • Canada (1)
Peak activity year
2021
Number of Unicorns
1
Number of Decacorns
1
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
10
Avg. valuation at time of investment
72M
Group Appearance index
1.00
Avg. company exit year
6
Avg. multiplicator
2.31
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Alterome Therapeutics 03 Apr 2024 Pharmaceutical, Biopharma Early Stage Venture 132M United States, California, San Diego
C2i Genomics 15 Apr 2021 Health Care, Health Diagnostics, Wellness, Genetics, Therapeutics Early Stage Venture 100M United States, New York, New York
Skycob 01 Aug 2016 Marketing Automation, Marketing, Market Research, Social Media Marketing, Brand Marketing, Email Marketing, Affiliate Marketing Seed 2M United States, California, San Francisco

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.